Glycocyamine betaine as an adjunct in the treatment of neuromuscular disease patients

J H ALDES
The Journal of the Arkansas Medical Society 1957 54(5):186-194

Bibliography

PubMed
PMID 13475190
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignIndexed clinical report; abstract unavailable
ModelHuman participants
SampleNot available in the indexed record
InterventionFormulation and dose require the original full report
DurationNot available in the indexed record
EndpointsHistorical or clinical context

What the study showed, in plain terms

Published in 1957, this source examined historical reports and formulation context. It is retained for source traceability. Abstract unavailable in PubMed and no accessible full report was verified for this summary. The paper title is not treated as sufficient evidence of efficacy, dose, safety or causality.

The indexed record verifies the publication and citation, but supplies no abstract. A quantitative effect or complete treatment result is not established from this record alone.

Abstract unavailable in PubMed and no accessible full report was verified for this summary. The paper title is not treated as sufficient evidence of efficacy, dose, safety or causality.

Continue with TMG Data Center

Continue with TMG Supplement: Trimethylglycine Benefits, Uses and Evidence

Key findings

  • The indexed record verifies the publication and citation, but supplies no abstract.
  • A quantitative effect or complete treatment result is not established from this record alone.
  • The recorded outcome domains were Historical or clinical context.

What this study can and cannot tell us

  • Abstract unavailable in PubMed and no accessible full report was verified for this summary. The paper title is not treated as sufficient evidence of efficacy, dose, safety or causality.
  • Source basis: Bibliographic data only; no abstract available. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Betaine: A Promising Natural Product for Neurological and Psychiatric Diseases
Ying Zhang et al. · Current neuropharmacology · 2026
Tier 4
Association of trimethylamine oxide and its precursors with cognitive impairment: a systematic review and meta-analysis
Caiyi Long et al. · Frontiers in aging neuroscience · 2024
Tier 2
An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients
D Knopman et al. · Alzheimer disease and associated disorders · 2001
Tier 4
Global DNA hypomethylation and its correlation to the betaine level in peripheral blood of patients with schizophrenia
Yui Murata et al. · Progress in neuro-psychopharmacology & biological psychiatry · 2020
Tier 4
Decoding Betaine: A Critical Analysis of Therapeutic Potential Compared with Marketing Hype-A Narrative Review
Grzegorz Nikrandt et al. · The Journal of nutrition · 2024
Tier 4
Betaine in human nutrition
Stuart A S Craig et al. · The American journal of clinical nutrition · 2004

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology